ProBeautyShield is a probiotic complex by SynBalance, specifically designed to support skin health with an improvement of atopic and acneic prone skins.
It has been clinically tested in two different clinical trial targeting Atopic Dermatitis and Acne. The first randomized double-blind placebo clinical trial has involved 80 adults (40 active/ 40 placebo), with atopic dermatitis (SCORAD: 15 – 25), affected by skin dryness, desquamation, erythema and itching. Checks were scheduled at T0, T28 and T56 (end of treatment) and T84 (1-month wash-out). Instrumental and clinical parameters determined the efficacy of the treatment: subjects showed improved smoothness, skin hydration and protection, self-perception, decreased SCORAD and pro-inflammatory markers associated to AD after only 28 days, with a positive trend up to T56 and maintenance of the effect at T84. Furthermore 80 subjects (40 active/ 40 placebo), with acne severity from 1 to 3 according to IGA scale, were recruited for a second randomized placebo controlled trial and took the probiotic supplement for 8 weeks (scheduled checks at T0, T28 and T56). For ethical reasons, all subjects used a gold standard cosmetic during the trial. Results reported a significant reduction of skin sebum and pH as well as an improvement of skin moisture. Better results were collected in terms of self-perception, acneic lesions and inflammatory status. The above strains have been previously proven to colonize and persist in the GI tract after the end of treatment, thus explaining the long-term clinical effect.
- > ProBeautyShield
ProBeautyShield
Discover characteristics, functionalities and scientific support of ProBeautyShield.
Thearapeutical Area(s): Skin health
Age/Gender: Adults
CFU/Dose: 3 billion(s)
Scientific reference(s)
Michelotti, A., Cestone, E., De Ponti, I., Giardina, S., Pisati, M., Spartà, E., & Tursi, F. (2021). Efficacy of a probiotic supplement in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled clinical trial. European Journal of Dermatology, 1(1)
Carlomagno F, Pesciaroli C, Cestone E, De Ponti I, Michelotti A, Tursi F. Clinical assessment on the effi cacy of a combined treatment targeting subjects with acne-prone skin. Our Dermatol Online. 2022;13(3):240-247.
The most performing strains have been selected through several in-vitro models as the production of post-biotic metabolites & B-group vitamins, anti-inflammatory & anti-oxidant capacity and anti-microbial activity against skin pathogens (S. epidermidis, S. aureus, P. acnes), L. plantarum PBS067, L. reuteri PBS072 and L. rhamnosus LRH020.
Presti, I., et al. ""Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect."" Applied microbiology and biotechnology 99.13 (2015): 5613-5626.
De Giani, A., Bovio, F., Forcella, M., Fusi, P., Sello, G., & Di Gennaro, P. (2019). Identification of a bacteriocin-like compound from Lactobacillus plantarum with antimicrobial activity and effects on normal and cancerogenic human intestinal cells. AMB Express, 9(1), 1-11.
